醫藥相關股逆市造好 藥明生物/平安好醫生/阿里健康/愛康/微創漲3%-8%
南韓及德國放寬禁閉措施後，新冠肺炎新增確診個案回升，市場憂慮全球各國過早放寬禁閉措施重啟經濟活動或會出現第二波新冠肺炎疫情，加上中美貿易前景不明朗，道指期貨續吐198點或0.8%報23,926。亞太區股市全面受壓，尤其是恆指曾吐465點或1.9%低見24,136，現造24,223元，回吐378點或1.5%，星股及澳股也吐1%-1.3%。
不過，本港醫藥相關股普遍逆升，尤其是平安好醫生(01833.HK)及阿里健康(00241.HK)高見114.3元及19.84元，現造114元及19.82元，續升4.3%及6%。
康希諾(06185.HK)曾升破上月尾所創上市高位168元，最高見176.3元，現造168元，續升3%。藥明生物(02269.HK)更連續第三天創上市高位，最高見130.8元，現造130.3元，續升2.6%；旗下藥明康德(02359.HK)高見114元，現造112.3元，續升1.4%。
無懼首季虧損擴至3.6億美元的百濟神州(06160.HK)升破百天線(93.84元)，最高見96.5元，現造96.25元，續升3.5%。君實生物(01877.HK)回升4.3%報38.7元，股價重越10天線(38.6元)。
威高股份(01066.HK)回升2.8%報12.3元；綠藥製藥(02186.HK)及聯邦制藥(03933.HK)高見4.03元7.32元，現造3.98元及7.25元，續升3.6%。三生製藥(01530.HK)高見9.1元，現造8.97元，續升1.2%。
愛康醫療(01789.HK)及春立醫療(01858.HK)高見22.4元及44.35元，現造22.25元及43.9元，回升7%及3.8%，後者重越10天及20天線。啟明醫療(02500.HK)升2.3%曾高見58.95元。微創醫療(00853.HK)回升8%報20.1元，僅次於3月16日所造上市高位20.4元。不過，兩大藍籌藥股中生(01177.HK)及石藥(01093.HK)隨大市跌逾1%。
中國外交部昨天就「中國黑客試圖竊取美國新冠肺炎疫苗成果」說法回應指，中國於新冠疫苗研究和治療方法方面均走在世界前列。據之前曾披露消息，中國四種國產新冠疫苗研發正齊頭並進，其中軍事科學院軍事醫學研究院陳薇院士團隊腺病毒載體重組疫苗，已於4月中進入二期臨床試驗，為全球首款進入II期試驗的疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
